Recent Finacing
Recent Raise
Upstream Bio develops and clinically advances UPB-101, a TSLP-receptor–binding human IgG1 monoclonal antibody, conducting Phase 1–2 trials in asthma and CRSwNP while advancing manufacturing and device development.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Upstream Bio.
